Jumanah Alshenaifi
YOU?
Author Swipe
View article: Proteotranscriptomic Analyses of Microsatellite-Stable Early-Onset Colorectal Cancer
Proteotranscriptomic Analyses of Microsatellite-Stable Early-Onset Colorectal Cancer Open
PURPOSE The prevalence and death rates of early-onset colorectal cancer (EOCRC) have been increasing at an alarming rate since 1994. Compared with late-onset colorectal cancer (LOCRC), EOCRC is more aggressive and resistant to treatment. D…
View article: Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer
Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer Open
Background Aberrant enhancer dynamics play a critical role in the initiation and progression of colorectal cancer (CRC). BRAF V600E -mutated metastatic CRC may be a unique subtype, exhibiting a strong epigenetic phenotype. Interestingly, b…
View article: Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer
Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer Open
MAPK pathway inhibitors (MAPKi) are increasingly used in the treatment of advanced colorectal cancer, but often produce short-lived responses in patients. Although acquired resistance by de novo mutations in tumors have been found to reduc…
View article: Young-onset Rectal Cancer
Young-onset Rectal Cancer Open
Objective: External exposures, the host, and the microbiome interact in oncology. We aimed to investigate tumoral microbiomes in young-onset rectal cancers (YORCs) for profiles potentially correlative with disease etiology and biology. Bac…
View article: Figure S2 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S2 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S2: Association of gene size and the fold increase in the frame-shift mutation rate of cases with MSS CRC.
View article: Figure S4 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S4 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S4: Top ten GO enrichment gene sets of ARID1A tumor DEGs demonstrates that most are immune processes related.
View article: Table S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Table S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Table S1
View article: Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Purpose:AT-rich interactive domain 1A (ARID1A) is commonly mutated in colorectal cancer, frequently resulting in truncation and loss of protein expression. ARID1A recruits MSH2 for mismatch repair during DNA replication. ARID1A defi…
View article: Figure S3 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S3 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S3. Association of gene size and the differential expression of IFN-γ pathway in genes commonly mutated in MSS CRC
View article: Table S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Table S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Table S1
View article: Figure S4 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S4 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S4: Top ten GO enrichment gene sets of ARID1A tumor DEGs demonstrates that most are immune processes related.
View article: Figure S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S1: Mutation Map of ARID1A gene in microsatellite-stable colorectal cancer patients.
View article: Figure S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S1: Mutation Map of ARID1A gene in microsatellite-stable colorectal cancer patients.
View article: Figure S2 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S2 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S2: Association of gene size and the fold increase in the frame-shift mutation rate of cases with MSS CRC.
View article: Figure S3 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Figure S3 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Supplementary Fig S3. Association of gene size and the differential expression of IFN-γ pathway in genes commonly mutated in MSS CRC
View article: Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Data from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Purpose:AT-rich interactive domain 1A (ARID1A) is commonly mutated in colorectal cancer, frequently resulting in truncation and loss of protein expression. ARID1A recruits MSH2 for mismatch repair during DNA replication. ARID1A defi…
View article: Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy Open
PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-path…
View article: ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Open
Purpose: AT-rich interactive domain 1A (ARID1A) is commonly mutated in colorectal cancer, frequently resulting in truncation and loss of protein expression. ARID1A recruits MSH2 for mismatch repair during DNA replication. ARID1A deficiency…
View article: Anomaly Detection Semi-Supervised Framework for Sepsis Treatment
Anomaly Detection Semi-Supervised Framework for Sepsis Treatment Open
Sepsis is one of the leading causes of morbidity and mortality in hospitals.Early diagnosis could substantially improve the patient outcomes and reduce the mortality rate.In this paper we propose a machine learning approach for anomaly det…